KDM5B-IN-4
Based on 1 Customer Validation
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 3046228-11-6
- Formula: C30H30N6O
- Molecular Weight:490.60
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
IC 50: 0.025 μM (Lysine demethylase 5B, KDM5B)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
9.532 μM
Compound: 11ad
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
| HepG2 | IC50 |
5.76 μM
Compound: 11ad
|
Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
| LNCaP | IC50 |
4.34 μM
Compound: 11ad
|
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
| MCF7 | IC50 |
6.77 μM
Compound: 11ad
|
Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
| MGC-803 | IC50 |
6.09 μM
Compound: 11ad
|
Antitumor activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antitumor activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
| PC-3 | IC50 |
2.18 μM
Compound: 11ad
|
Antitumor activity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antitumor activity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 36931124] |
KDM5B-IN-4 (20 μM, 72 h) has targeted inhibition of KDM5B and induction of H3K4me1/2/3 production in PC-3 cells[1].
KDM5B-IN-4 (0-20 μM; 72 h) not only targets KDM5B in cells, but also induces H3K4me1/2/3 accumulation in PC-3 cells[1].
KDM5B-IN-4 (0-10 μM, 0-24 h) inhibited the proliferation and migration of prostate cancer cells, blocked the PC-3 cycle in the G2/M phase, and induced apoptosis of PC-3 cells to a certain extent[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC-3
-
Concentration:0, 2.5, 5, 10, 20 μM
-
Incubation Time:72 h
-
Result:Induced the concentrations of H3K4me1/2/3 significantly different from those of the control, and the results obtained were similar to those obtained using the CPI-455 positive control.
Had no significant effect on P110α, P85, and pAKT at low concentration levels (0-10μM), and P110α, P85, and pAKT were significantly decreased when 11ad was at high concentration (20 μM).
-
Cell Line:PC-3
-
Concentration:0, 5, 10 μM
-
Incubation Time:0, 6, 12, 24 h
-
Result:Inhibited colony formation in a dosedependent manner, especially at high doses (10 μM).
-
Cell Line:PC-3
-
Concentration:0, 2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Blocked the cell cycle at G2/M phase in 10 μM.
-
Cell Line:PC-3
-
Concentration:0, 2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Induced PC-3 cell apoptosis in a dose-dependent manner (7.58%, 26.14%, 28.20%, 45.66%).
KDM5B-IN-4 (50 mg/kg, i.g., 50 mg/kg/d, 25 days) did not cause noticeable damage to the mice, confirming that 11ad had no significant toxicity or side effects in vivo[1].
Pharmacokinetic Analysis in KDM5B-IN-4 (compound 11ad) Xenograft Model[1]
| Parameter | T1/2 (h) | Tmax (h) | Cmax (ng/mL) | AUC0-t (h*ng/mL) | MRT0-t (h) | Vz (L/kg) | Cl (L h/kg) | F |
| p.o. (25mg/kg) | 5.30 | 6.0 | 411.67 | 3024.33 | 6.90 | / | / | 20.28% |
| i.v. (5mg/kg) | 2.95 | 0.083 | 551.67 | 44437.67 | 10.29 | 19.51 | 0.49 | / |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC-3 xenograft model in male Spraguee-Dawley rats[1].
-
Dosage:25, 50 mg/kg
-
Administration:Intragastric administration to mice (i.g.) for 25 days, administered once daily.
-
Result:Compared with NaCl treatment, treatment with 25 mg/kg and 50 mg/kg significantly decreased tumor volume.
-
Animal Model:PC-3 xenograft model in male Spraguee-Dawley rats[1].
-
Dosage:2 g/kg
-
Administration:Intragastric administration to mice (i.g.) for 14 days, administered once daily.
-
Result:No significant loss of major organs in the high-dose and low-dose groups.
Chemical Information
-
CAS No. 3046228-11-6
-
Appearance Solid
-
Molecular Weight 490.60
-
Formula C30H30N6O
-
Color White to off-white
-
SMILES
CN1CCN(CC1)CCNC(C2=CC(C3=CC=C4C=CC=CC4=C3)=NC5=C2C=NN5C6=CC=CC=C6)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 33.33 mg/mL (67.94 mM; ultrasonic and adjust pH to 2 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.33 mg/mL (6.79 mM); Clear solution
This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3.33 mg/mL (6.79 mM); Clear solution
This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0383 mL | 10.1916 mL | 20.3832 mL | 50.9580 mL |
| 5 mM | 0.4077 mL | 2.0383 mL | 4.0766 mL | 10.1916 mL | |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0383 mL | 5.0958 mL | |
| 15 mM | 0.1359 mL | 0.6794 mL | 1.3589 mL | 3.3972 mL | |
| 20 mM | 0.1019 mL | 0.5096 mL | 1.0192 mL | 2.5479 mL | |
| 25 mM | 0.0815 mL | 0.4077 mL | 0.8153 mL | 2.0383 mL | |
| 30 mM | 0.0679 mL | 0.3397 mL | 0.6794 mL | 1.6986 mL | |
| 40 mM | 0.0510 mL | 0.2548 mL | 0.5096 mL | 1.2740 mL | |
| 50 mM | 0.0408 mL | 0.2038 mL | 0.4077 mL | 1.0192 mL | |
| 60 mM | 0.0340 mL | 0.1699 mL | 0.3397 mL | 0.8493 mL |